TY - JOUR
T1 - Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer
T2 - The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy
AU - Blair, Alex B.
AU - Rosati, Lauren M.
AU - Rezaee, Neda
AU - Gemenetzis, Georgios
AU - Zheng, Lei
AU - Hruban, Ralph H.
AU - Cameron, John L.
AU - Weiss, Matthew J.
AU - Wolfgang, Christopher L.
AU - Herman, Joseph M.
AU - He, Jin
N1 - Funding Information:
A.B. was supported with the NCI T32 grant #5T32CA126607-08.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/5
Y1 - 2018/5
N2 - Background: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy. Methods: Patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses. Results: A total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P =.017) and a require vascular resection (54% vs 37%, P =.027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P <.001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P =.471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group. Conclusion: Compared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.
AB - Background: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy. Methods: Patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma who underwent neoadjuvant chemotherapy with stereotactic body radiation therapy or chemoradiation therapy followed by pancreatectomy at the Johns Hopkins Hospital between 2008 and 2015 were included. Predictive factors for severe complications (Clavien grade ≥ III) were assessed by univariate and multivariate analyses. Results: A total of 168 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma underwent neoadjuvant chemotherapy and RT followed by pancreatectomy. Sixty-one (36%) patients underwent stereotactic body radiation therapy and 107 (64%) patients received chemoradiation therapy. Compared with the chemoradiation therapy cohort, the neoadjuvant stereotactic body radiation therapy cohort was more likely to have locally advanced pancreatic ductal adenocarcinoma (62% vs 43% P =.017) and a require vascular resection (54% vs 37%, P =.027). Multiagent chemotherapy was used more commonly in the stereotactic body radiation therapy cohort (97% vs 75%, P <.001). Postoperative complications (Clavien grade ≥ III 23% vs 28%, P =.471) were similar between stereotactic body radiation therapy and chemoradiation therapy cohort. No significant difference in postoperative bleeding or infection was noted in either group. Conclusion: Compared with chemoradiation therapy, neoadjuvant stereotactic body radiation therapy appears to offer equivalent rates of perioperative complications in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma despite a greater percentage of locally advanced disease and more complex operative treatment.
UR - http://www.scopus.com/inward/record.url?scp=85040937698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040937698&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2017.11.027
DO - 10.1016/j.surg.2017.11.027
M3 - Article
C2 - 29395234
AN - SCOPUS:85040937698
SN - 0039-6060
VL - 163
SP - 1090
EP - 1096
JO - Surgery (United States)
JF - Surgery (United States)
IS - 5
ER -